AGIO Agios Pharmaceuticals Inc.

32.43
-1.13  -3%
Previous Close 33.56
Open 33.46
Price To Book 4.26
Market Cap 1,909,577,117
Shares 58,883,044
Volume 1,381,318
Short Ratio
Av. Daily Volume 814,418
Stock charts supplied by TradingView

NewsSee all news

  1. Agios Announces Pricing of $256 Million Public Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it has priced an underwritten public offering of 8,250,000 shares of common stock at a price to the

  2. Agios Announces Proposed Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 7.5 million shares of its common

  3. Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting

    – Important Translational Data for TIBSOVO® Underscore the High Clinical and Molecular Remissions Rate Observed in Combination with Azacitidine in IDH1 Mutant AML and Expand Understanding of Resistance Mechanisms – –

  4. Agios Reports Business Highlights and Third Quarter 2019 Financial Results

    – TIBSOVO® Net Revenue of $17.4 Million; 27% Growth from Q2 2019 – – Reported Positive Phase 3 ClarIDHy Results for TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission Planned by Year-End – –

  5. Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

    – Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating AG-270 in Combination

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 4Q 2019.
AG-348 - Mitapivat
Thalassemia
FDA Approval announced July 20, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 3 enrolment to be completed 2019.
AG-348 (ACTIVATE)
Pyruvate kinase deficiency
Phase 3 enrolment to be completed 2020.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
sNDA filing due to be filed following final overall survival analysis mid-2020.
AG-120 Ivosidenib
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 data presented at AACR-NCI-EORTC October 27, 2019. Trial is ongoing.
AG-270
Solid tumors
Phase 3 trial to be initiated YE 2019.
Vorasidenib (AG-881)
Glioma
FDA Approval announced May 2, 2019.
Ivosidenib
Frontline AML with IDH1 mutation
Phase 1 updated data due at Society for Neuro-Oncology meeting November 22-24, 2019.
Ivosidenib and Vorasidenib (AG-881)
IDHm low-grade glioma
Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib
IDH1 mutant newly diagnosed AML ineligible for standard therapies
Phase 1 updated data at ASH December 9, 2019 at 10:30 a.m. ET.
Ivosidenib and azacitidine ( Vidaza)
Newly diagnosed AML with an IDH1 mutation
Phase 2 data to be presented at ASH December 9, 2019 from 6pm ET.
AG-348 - Mitapivat (DRIVE)
Pyruvate Kinase Deficiency

Latest News

  1. Agios Announces Pricing of $256 Million Public Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it has priced an underwritten public offering of 8,250,000 shares of common stock at a price to the

  2. Agios Announces Proposed Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 7.5 million shares of its common

  3. Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting

    – Important Translational Data for TIBSOVO® Underscore the High Clinical and Molecular Remissions Rate Observed in Combination with Azacitidine in IDH1 Mutant AML and Expand Understanding of Resistance Mechanisms – –

  4. Agios Reports Business Highlights and Third Quarter 2019 Financial Results

    – TIBSOVO® Net Revenue of $17.4 Million; 27% Growth from Q2 2019 – – Reported Positive Phase 3 ClarIDHy Results for TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission Planned by Year-End – –

  5. Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

    – Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating AG-270 in Combination

  6. Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019

    CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company

  7. Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference

    CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the

  8. Data from Agios' Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

    – TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo – – TIBSOVO® Patients Had

  9. Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

    CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the

  10. Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine

    –  Maximum Hemoglobin Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum Hemoglobin Increase was 3.4 g/dL – – Hemoglobin Responses Maintained in 19 Patients in the Extension

  11. Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019

    CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is